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INTRODUCTION 
 
 Hepatitis B virus (HBV)  infection is an important  health problem 
worldwide and more so with chronic kidney disease patients. More than two    
billion people are infected with Hepatitis B virus all over the world and 
about 350 million people are chronic carriers(1,2). The prevalence of  HBV 
infection is high in haemodialysis population  compared to general 
population in view of increased  exposure to blood products, contamination 
through needles and haemodialysis machine surface contamination (3). 
However with the availability of Hepatitis B vaccination, usage of 
erythropoietin and screening of blood products, dedicated machine with 
universal precautions   the incidence of HBV infection is reduced in this 
population.Still HBV infection is a persistent problem and the immune 
response to vaccination is impaired.The seroconversion rate following 
Hepatitis B vaccination in healthy  individuals is morethan 90% but in 
patients undergoing haemodialysis it is about 50% -60% (4) . The centre for 
disease control (CDC) and prevention recommends Hepatitis B vaccination 
for patients  with chronic kidney disease not requiring dialysis  3 doses  at 
0,1 and 6 months with 20 µg of each dose and for patients undergoing 
dialysis  4 doses at 0,1,2 and 6 months with 40 µg (5,6).  
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 This study was done to measure the antiHBS antibody titre following 
4  doses of  40 µg  of Hepatitis B vaccine in haemodialysis patients  and 
compare with 3 doses of 20 µg in healthy controls.  
  
  
3 
 
 
AIMS AND OBJECTIVES 
   
1. To find out the sero conversion rate following hepatitis B 
vaccination in Chronic  kidney disease population with current 
immunization schedule and compare it with  adult  healthy  
volunteers.   
 
2. To analyze the  impact of various factors  on immune response  
following  hepatitis  B  vaccination. 
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REVIEW OF LITERATURE 
 
 Infection is the second most common cause death in chronic kidney 
disease next to cardiovascular cause.This is because chronic kidney disease 
patients (CKD) are immunosuppressed with impaired immune response of 
both cellular and humoral immunity to infections. CKD patients when they 
undergo haemodialysis they are much more prone for infections than 
general population in view of exposure to blood .Infection due to hepatitis B 
virus (HBV ) is one of the common infection that occurs in dialysis patients 
as they are blood borne pathogens. 
 
 HBV infection is a problem throughout the world and more than 2 
billion people are affected. India is classified as having  intermediate 
endemicity  for HBsAg carrier state (2–7%) (1)  
 
Hepatitis B Virus is a small DNA Virus with 7 genotypes. It’s 
diameter is 45nm. The major route of transmission is through direct contact 
with blood or secretions. Also vertical transmission can also occur. In India 
the common route of HBV infection is vertical followed by horizontal 
transmission. The major genotypes are A&D with reports of C from eastern 
part of India (7,8). The virus can live upto one week in the environment. After 
infection with Hepatitis B virus first antigen to appear in the blood is 
Hepatitis B surface antigen (HBsAg). This occur even before elevation of 
transaminases. This is present for 1-2 months commonly and rarely upto 6 
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months following which (anti HBS) antibody to HBsAg occurs which 
persists throughout life. During the window period, i.e. between the 
disappearance of HBsAg and appearance of anti HBS, the antibody to core 
antigen (anti HBC) present and that will be the  only evidence for HBV 
infection. Initially IgM anti HBC antibodies appeared 1-2 weeks after 
HBsAg occurred followed by IgG anti HBC antibodies which persists life 
long. HBeAg, a serologic marker of active viral replication started 
appearing shortly after HBsAg and becomes undetectable before the 
disappearance of HBsAg. HBcAg is not detectable in the serum. Anti HBs 
is a protective antibody with the recovery from acute infection. HBsAg 
disappeared and antiHBs persists.Wherein,the  persistence of HBsAg  for 
more than 6 months is taken as chronic infection and anti HBs titer is not 
detected or present in very low level. (9,10) 
                              Hepatitis B infection 
 
Months after exposure 
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 Hepatitis B infection can cause acute hepatitis, chronic hepatitis, 
cirrhosis liver and hepatocellular carcinoma. Hepatitis B virus infection is 
haemodialysis patients. Compared to earlier date, the incidence of HBV 
infection in haemodialysis unit has come down markedly due to more usage 
of erythropoietin rather than blood transfusion, routine screening of blood 
before transfusion and following universal precautions. But still the 
incidence is haemodialysis patients is more than general population. It is 
due to repeated exposure to blood and blood products, contamination 
through haemodialysis machine and usage of multidose vial in HD Unit. 
 
Incidence:  
            Incidence of HBV infection in haemodialysis unit in developed 
countries has come down to < 1 % following universal precautions and 
intensive vaccination schedule  and in  less developed countries the 
incidence is 10-20%. (4,11) . Jha et al reported the incidence in India in 
haemodialysis patients  as 20 – 45%.  
 In haemodialysis patients once infection occurs it is usually 
asymptomatic and liver enzymes are not elevated. 50-60% of them became 
chronic carriers and acts as a reservoir spreading the infection to other 
patients and medical staff personnel. 
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Prevention of HBV Infection in Haemodialysis Unit: (HD) 
1. Universal Precautions: 
 According to CDC guidelines universal precautions have to be 
followed strictly in haemodialysis . Proper hand washing between patients, 
wearing eye goggles, gowns and gloves and changing of gloves between 
patients are essential in HD unit. 
 
2. Segregation of HD Machine: 
 Patients infected with Hepatitis B virus infection should be dialyzed 
in a separate machine in a segregated room as per CDC guide lines. This is 
done to avoid contamination of  HD machine surface to other machines and 
hence patients. Also multidose vials and sharing of stationary things 
between HBV positive and negative patients should be strictly avoided. 
 
3. HBV Vaccination: 
 For the effective control of HBV infection in both general population 
and in HD unit, HBV vaccination plays an important role. Krugman in 1970 
first detected that HBsAg is immunogenic and antibodies against HBsAg 
are protective. Thus HBV vaccination was found out. Initially it was 
obtained from the plasma of patients infected with Hepatitis B infection. But 
it increases the transmission of other infections also. Now, using 
recombinant technology, HBV vaccine is obtained. It has high patient safety 
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profile and highly immunogenic and  when it given deep intramuscularly 3 
doses at an interval of 0, 1, 6 months, the immune response will be more 
than 90%. (12,13) 
 
In HD unit where the incidence of HBV infection is more, it is 
mandatory to give HBV vaccine to all HBV negative serology patients. 
CDC (Centre for Disease Control and Prevention) recommends HBV 
vaccination to be strictly adhered to as per intensified schedule. 
 
Accordingly, 40 ug of HBV vaccine deep intra muscularly with 20 ug 
in each arm on 0,1,2 and 6 months to be given. Recently updated CDC 
guideline also recommends HBV vaccine to diabetic patients who are 
younger than 60 years old. Anti HBS titer to be checked 4 weeks after the 
last dose of vaccine and if less than 10mIU/m a booster dose has to be 
given. Periodically anti HBs titer to be measured and the titer should be 
maintained more than 10mIU/ml. 
 
In spite of 40ug of HBV vaccine with four doses the immune 
response rate in haemodialysis patients is less 50-60% (14-16). Even in 
patients who had immune response is >10mIU/ml, the anti HBs titer fall 
rapidly and thus protective for short duration only. The peaking level of anti 
HBs titer was also lower in HD patients compared to general 
population.(17,18) 
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If the needle used in HBV positive patients was inadvertently pricked 
the other patient or medical staff, immediately we need to check the anti 
HBs titer which is a protective antibody as the rate of transmission via 
needle stick is 30%. If the anti HBs titer is less than 10mIU/ml, they have to 
be given a booster dose of HBV vaccine. Also immunoglobulin need to be 
given immediately. 
 
HBV infection can also be transmitted from medical staff if they are 
HBV positive. Hence it is mandatory that all medical staff in HD room 
should be vaccinated with 3 doses of 20ug each on 0,1 and 6 months and the 
titer should be checked periodically and if not protective level booster dose 
has to be given. (19, 20) 
 
Immune response following HBV vaccination in haemodialysis patients: 
 Normally, following vaccination, the antigen in the vaccine is 
presented to T and B cells through antigen presenting cells such as dendritic 
cells. When T cells come in contact with HBsAg with increasd expression 
of costimulation ,T cells get activated  and proliferation with the release of 
cytokines occur.The cytokines stimulate B cells which produces antibodies 
to HBsAg. 
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 The adjuvant used in HBV vaccine is aluminium. The exact 
mechanism is unclear. It increases the uptake of antigen by antigen 
presenting cells, increases cytokine release from activated ‘T’ cells and 
increased proliferation of antigen specific ‘T’ cells. (21,22) 
  
                                         HBV vaccine mechanism 
 
                                            In normal persons 
 
 
 
HBV vaccine with 
      HBsAg and adjuvant 
 
          By 6APC 
 
HBsAg 
 
 
 
Helper and memory 
T cells 
 
 
 
         Cytokines 
 
 
 
    Stimulation of Bcells 
 
 
 
        AntiHBs 
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 This normal immune response following vaccination is impaired in 
dialysis patients. (21) There is poor response following HBV vaccination 
even with intensified schedule and hence there is difficulty in controlling the 
infection in HD unit. The exact mechanism for the poor immune response is 
not known. However, Lim WH et al (22) in their study had shown that the 
function of the dendritic cell which is the antigen presenting cell presenting 
antigen to T cell is impaired in uraemia. It was also found that there is 
reduced activation of  memory cells and the immune response has to depend 
only on circulating T cells in chronic kidney disease patients.(11,12,24) 
 
 Following vaccination in dialysis patients, the immune response is 
less with only 50-60% immune responders. The peak concentration of 
antiHBs titer is less and there is rapid fall of the titer in CKD patients. Also 
rapid seroconversion is impaired in such population and hence more 
susceptible for HBV infection. Hence patients need to be monitored 
frequently and booster doses have to be given repeatedly until the 
seroprotective rate of > 10mIU/ml.(25-27) 
 
 Serez S et al and Ramezani A et al in their studies had shown that the 
antiHBs titer of > 100 mIU/ml was protective and persisted for atleast one 
year, so that repeated booster doses can be avoided.(28-30) 
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Factors influencing the immune response: 
 There are various factors that negatively influence the immune 
response in CKD patients following vaccination. 
 
1. Diabetic Mellitus and Immune response: 
Diabetes mellitus is an immunocompromised state with reduced 
immune response to HBV vaccination. DM in CKD patients undergoing 
dialysis has an important factor that negatively influences the 
seroconversion. 
 
In diabetes mellitus, there is reduction in the number of helper T cells 
and also impaired antigen presentation by dendritic cells. (30,31) 
 
Sarah F. Schillie et al in their meta analysis including 2 randomized 
trials involving patients with and without chronic kidney disease on dialysis 
reported the immune response rate as 41.8% to 85.5% with mean of 60.1% 
in diabetics compared to 61.8% to 87.5% with mean of 75.1% in non-
diabetic patients undergoing haemodialysis. Douvin et al in their studies had 
shown the immune response in diabetics following HBV vaccination was 
94.4% using 4 doses of 0, 1, 2, 12 months of 20ug. Where in Bouter et al 
showed the response rate of 75.1%. The difference in response between the 
studies is due to difference in age group involved in both studies. Patients 
were much older in the study group with less immune response compared to 
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those with good immune response. In this meta analysis it was concluded 
that the older diabetic patients have less immune response compared to 
young diabetic individuals undergoing dialysis. There was association 
between the blood sugar control and duration of dialysis with immune 
response.(32, 33) 
 
2) Malnutrition and Immune response: 
 The incidence of malnutrition of varying degrees in haemodialysis 
patients is high compared to non-dialysis patients. Many studies have 
proven beyond doubt that malnutrition negatively influences the immune 
response in dialysis patients. Malnutrition leads to inability to form 
antibodies following vaccination.(34,35) 
 
Fernandez et al (36) showed the negative impact of malnutrition on 
immune response following HBV vaccination in dialysis patients. 64 
patients undergoing haemodialysis were included and nutritional assessment 
done by measuring serum albumin level. The immune response rate was 
about 70% in patients with serum albumin of 4-4.5 gm/dl compared to only 
12.5% in those with albumin of 3.01 to 3.5 gm/dl. In this study he also 
showed that the mortality is high in patients with low albumin and non-
responders. 
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 Fabrizi et al (37) did meta analysis of seven studies on  the impact of 
nutritional status on HBV  vaccination response  in CKD patients. Study 
results showed that the poor nutritional status as  estimated by serum 
albumin levels was  an independent and adverse factor on immune response  
after HBV vaccination in chronic kidney disease patients. 
 
Age and Immune response: 
 It has been shown in many studies that the immune response was low 
in advanced age in dialysis patients.With aging both cellular and humoral 
immunity reduced following antigenic stimulation.This is because of age 
related changes in immune system. (38,39) 
 
Hans Kohler in his study reported that the association of less immune 
response following vaccination in dialysis patients was seen only in males 
and not in females. (40) 
 
Fabrizi et al in the meta analysis of immune response in dialysis 
patients had found the negative correlation of age and immune response 
with overall relative risk was 0.74 in older dialysis patients.(41) 
 
Some studies showed no association of advanced age and reduced 
immune response of older and younger dialysis patients.(42-44) 
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4) Immune response in early CKD: 
 It is well proven in many studies that the immune response following 
HBV vaccination was better in patients with early CKD staging compared to 
patients undergoing dialysis.(45) 
 
 Da Roza G et al (46) in a study of about 165 patients evaluated various 
factors influencing the immune response. The patients included were 
predialysis group with varying levels of GFR. The sero conversion rate in 
this group was 82% compared to vaccination to patients already initiated on 
haemodialysis, the response rate was 40-70%. In this study, it was shown 
that the higher the GFR, the higher the immune response. Agrawal S.K. et al 
in their study (47) showed a significant difference in sero conversion rate 
between patients with mild and severe renalfailure based on serum 
creatinine levels. 
 One Indian study by Shireen Siddique et a (48)  analysed the sero 
protective rate following HBV vaccination in CKD patients with varying 
levels of serum creatinine stratified as mild, moderate chronic kidney 
disease and end stage renal disease. They found that the seroprotection was 
found in 90-100% of patients with mild and moderate CKD and 54.5% to 
71% in patients with end stage renal disease. Therefore it is better to start 
HBV vaccination in CKD stage III itself when the immune response is 
good. 
  
16 
 
 
5) Obesity and Immune Response: 
 In obese individuals it was found that the immune response was lesser 
compared to non-obese patients. Reduced blood flow to adipose delay the 
antigen presentation to T cells leading to less immune response. Also the 
needle length may be shorter so that it may not pass through the fat and 
reach the muscle.(17) 
 
6) Gender difference and immune response: 
 Most of the studies did not reveal any significant difference in 
immune response between different gender following vaccination. (26,49) 
Hans Kohler had observed in his study of HBV vaccination response 
in dialysis patients that the response was more in female patients than in 
males but it was not statistically significant.(40) 
Other factors such as native kidney disease, duration of dialysis and 
haematocrit had no effect on immune response following vaccination.(48) 
 
Strategies to improve seroconversion rate: 
 In spite of higher doses of HBV vaccine in CKD patients on dialysis. 
the immune response rate was low and hence various methods have been 
adopted to increase immunogenicity. 
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1. Adjuventation: 
 Adjuvants are the substances that are added to the vaccine to increase 
immunogenicity. In the standard HBV vaccine, the adjuvant used is 
aluminium and  the mechanism of which is unclear. Probably it stimulates T 
cells to increase cytokine release and hence increase B cell stimulation of 
antibody production. 
 
 Newer vaccines have been developed  using different adjuvants that 
increase the antibody production rapidly, at a higher level and also 
persistently.  
 
HBASO4: 
 NCT Kong in this study (50) evaluated the immune response in dialysis 
patients following adjuvant HBV vaccine HBV-AS04 and compared the 
response to 4 doses of 40ug of standard HBV vaccine. The immune 
response rate was rapid, higher and more persistent requiring less booster 
doses compared to standard vaccine. The antibody was persistent upto 42 
months. 
 
 HBAS04 consists of recombinant HBV vaccine, aluminium 
phosphate and lipopolysaccharide content. This was obtained from the cell 
wall of Salmonella Minnesota (51) which was detoxified and then 
monophosphoryl lipid is obtained. This lipid content is added to the 
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HBAS04 vaccine.HBAS04 has been approved in Europe since 2005 for 
primary vaccination in patients with CKD of both dialysis and non-dialysis 
patients above the age of 15 years. 
 
In this study  NCT Kong had included 165 patients with 82 and 83 
patients were given HBAS04 and standard HBV vaccine respectively. 
Single dose of HBAS04 and double the dose (40ug) of standard vaccine 
were given on 0, 1, 2 and 6 months to dialysis patients. They were followed 
up for 42 months. The sero protection rate at 1 month after completion of 
the vaccine schedule was similar 92.4 % vs 87%  between 2 groups and 
there was no statistical difference between the groups.  
 
These patients when followed up till 42 months had shown decline in 
anti HBs titer level but it was less with HBAS04 than standard vaccine so 
that the seroprotective level of titer (>100mIU/ml in this study) was present 
in 54.1% compared to 29% in standard vaccine at the end of 42 months. 
Therefore the requirement of booster doses ws less with HBAS04. The 
reactions that occurred with booster doses included minor symptoms like 
fatigue and pain at the infection site. Serious adverse effects like death and 
all happened rarely due to cardiovascular events. 
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HBAS02: 
 Another adjuvented vaccine in use is HBAS02. It consists of 
recombinant HBsAg with monophosphoryl lipid and Qs21. Qs21 increases 
the immunogenicity and it is a purified product obtained from the bark of a 
tree Quillaja Saponavia. HBAS02 is an oil based emulsion and does not 
contain aluminium.(51) 
 
 Murielle surquin in his study (52) included about 300 dialysis patients 
and compared 3 doses of HBAS02 with HB-AS04. The author reported that 
the sero protection rate (>100 mIU/ml) was rapid and higher at 1,2 and 7th 
month of vaccination. In terms of persistence of anti HBs titer, it was more 
with HB-AS02 at the end of 12 months (93.6%) compared to 78.6% with 
HB-AS04. 
 
 Monophosphoryl content of these adjuvented vaccines acts by 
binding to Toll like receptor-4 on antigen presenting cells. This leads to 
increased maturation and activation of the APCs and also enhances the 
expressionof costimulatory molecules on these cells. This further causes 
increased activation and proliferation of T cells with increased cytokines 
and hence enhanced antibody production. 
 
 Katherine A. Barraclough(53) analysed the immune response following 
HBAS04, HBAS02 and standard HBV vaccine in dialysis patients and 
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concluded by mentioning that the ability of adjuvented vaccines to improve 
the seroprotection rate of dialysis patients needs to be proven. 
 
 Also meta analysis    done by  Fabrizio Fabrizi et al (54)  to evaluate 
the efficacy and safety of adjuvantation for HBV  vaccine in patients with 
chronic kidney disease. He analysed ten studies and  only prospective 
randomized  trials  were included.It did not reveal any significant increase in 
seroprotection rate with  adjuvanted vaccine  compared to control group  of  
standard HBV recombinant vaccine.The results do not support for  
adjuvantation as a strategy to increase the seroprotective rate of  HBV 
vaccine  in this high-risk population. 
 
2. Route of Administration: 
 HBV vaccine is given deep intramuscularly in all patients and in 
general population. Analysis in most of the studies was done following 
intramuscular route of administration of HBV vaccine. There are few 
clinical trials with intra dermal administration HBV vaccination as a way of 
increasing the immunogenicity is CKD patients.  
 
 In the skin there is higher concentration of both resident as well as 
recruited antigen presenting cells which can increase the immune response 
following vaccination more than in skeletal muscle. That is the rationale of 
giving intra dermal route rather than intramuscular route. 
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 Katherine Barraclough (53) in their study reported that in dialysis 
patients who failed to respond to primary HBV vaccination with 
intramuscular rate, when given repeated doses of the vaccine intra dermally, 
was found to have better immune response rate. It was also shown that not 
only seroconversion rate but also the peak antibody titer and persistence of 
the antibodies were all found to have been more with intra dermal 
administration rather than intramuscular rate. 
 
 One Indian study from CMC, Vellore done by U. Anandh et al (55) had 
compared twice a week intra dermal administration to once a week 
intradermal administration of HBV vaccine. It was a randomized controlled 
trial. 85 patients were included and 77 completed the study. It was found 
that the sero protection rate was 77.8% with a twice a week ID 
administration compared to once a week ID vaccine. The immune response 
was found to be increased in patients receiving erythropoietin than those not 
receiving erythropoietin(78.1% vs 60%). The highest response rate was 
those getting twice a week ID vaccine as well as EPO also (86.7%). 
 
 In another study from Thailand (16), where they compared the ID 
administration with  IM of  HBV vaccination. It was reported that at 7th 
month the sero protective rate with ID route was 92% compared to 69% 
with IM route. 
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 However the current guide lines advice against ID vaccination in 
view of insufficient data to support. 
 
3) Addition of Growth Factor: 
 It has been found that addition of growth factor such as granulocyte 
macrophage colony stimulating factor (GM CSF) to HBV enhances the 
immune response. The exact mechanism is not clear but the proposed 
mechanism is by giving GM-CSF macrophages got activated, increased 
MHC class II expression on antigen presenting cells and enhance T and B 
cells activation and hence immune response. The dose of GM-CSF varies 
from 20-300ug.(56) 
 
4) Role of Erythropoietin: 
 Erythropoietin plays a role in enhancing the immune response to 
HBV vaccine in dialysis patients by its effect on humoral and cellular 
immune system. Liu et al in their study showed that the immune response to 
HBV vaccine was enhanced by recombinant EPO.(57,58) 
 
 Also in  the study by U. Anandh (55)  showed that seroprotective rate 
was more in those getting EPO (78.1%) compared to those not getting EPO 
(60%). 
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 It was also shown that intravenous iron therapy reduces the immune 
response. 
 
Role of Levamisole 
 Levamisole is an immune modulator which increases the proliferation 
of natural killer cells and activated T cells enhancing the immune response 
following vaccination.(59,60) 
 
Alavian and Tabatabaei in their metaanalysis had shown that when 
Levamisole was used as an adjuvant to HBV vaccine, the seroprotection rate 
was enhanced.(61) 
 
To summarize, the incidence of HBV infection is still high in HD 
and it is highly recommended that intensified schedule of HBV vaccine to 
be given to all haemodialysis patients. It should be started in early CKD 
before the initiation of dialysis so that the response will be good. Anti HBs 
titer monitoring and regular booster doses are essential to maintain the 
seroprotectivity. Addition of adjuvants are novel strategies but need to be 
proven beyond doubt before  regular use. Addition of growth factors, intra 
dermal administration may increase the immune response. 
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MATERIALS AND METHODS 
 
 This is a prospective comparative study comparing  the sero 
conversion rate using 4 doses of  40µg of recombinant Hepatitis B virus  
vaccine (HBV  vaccine) administered to chronic kidney disease Stage-V 
patients undergoing haemodialysis  to healthy adult volunteers with 3 doses 
of 20µg  recombinant HBV   vaccine.  
 
 Study period was between Feb.2012 to January 2014. 
 
Inclusion Criteria:  
 
1. All patients with CKD-V undergoing maintenance haemodialysis at 
Madras Medical College & Rajiv Gandhi Govt. General Hospital who 
were given 4 doses of 40 µg  of HBV Vaccine. 
2. Healthy adult volunteers who were .given  3 doses of HBV  vaccine. 
 
 Sero conversion rate was studied in both the groups 1 month after 
completion of vaccination schedule. 
 
Exclusion Criteria: 
1. Patients undergoing haemodialysis with HBSAg serology   positive. 
2. Patients already initiated on vaccination elsewhere and on irregular 
schedule. 
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• HBV  vaccine was initiated on all patients undergoing maintenance 
haemodialysis with HBSAg negative serology at Madras Medical 
College & Rajiv Gandhi Govt. General Hospital with 40µg of 
recombinant  HBV   vaccine on 0, 1, 2, 6 months. (20 µg deep 
intramuscular in each deltoid). 
• The control group included normal healthy adult volunteers  negative 
for HBSAg  serology.They were  given 20µg of HBV vaccine deep 
intramuscular  on 0, 1 and 6 months. 
• Basic demographic data such as age, gender, BMI, duration of 
dialysis comorbid conditions such as DM, HT, CAD, CVA, history of  
smoking were collected. Clinical examination and  laboratory 
parameters such as complete haemogram, blood sugar, urea, serum 
creatinine, serum electrolytes, serum total proteins, serum albumin, 
AST, ALT, bilirubin, lipid profile, Hepatitis C and  HIV serology and  
calculation of URR were done. 
• Hepatitis B (HBsAg) serology was done by HBsAg-card test  which  
is a rapid, qualitative   one-step immunoassay with a  combination of 
monoclonal-dye conjugate (colloidal gold) with polyclonal solid 
phase antibodies to  identify HBsAg .This test has a  high degree of 
sensitivity. The  whole blood  was added directly to the sample pad. 
When  the  sample flowed through,  the labelled antibody-dye 
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conjugate bound to HBsAg resulting in an antibody-antigen complex. 
The pad was in contact with a chromatographic test strip that contains 
a region of immobilised polyclonal anti-HBsAg antibody in the test 
line. The antibody-antigen complex  formed  a pink line of 
immobilised complex by the presence of antibody in the test 
line,showing the presence of HBsAg in the sample ;otherwise the  test 
line will remain clear.  
 
• Estimation of anti HBs titer four weeks after  HBV  vaccination was 
done by ELISA method.It was a one-step incubation with double 
antigen sandwich principle for  quantitative detection of antibodies 
to hepatitis  B  surface antigen  in  serum .The anti-HBs ELISA kit 
used had  polystyrene microwell  strips pre-coated with recombinant  
HBsAg. Patient’s serum was then added to the microwell  with 
another  recombinant HBsAg  conjugated  with Horse radish 
peroxidase (HRP) . With the presence of anti-HBs in the sample, 
both the antigens would  bound to the antibody and during 
incubation, the specific  immune complex formed was captured on 
the solid phase.After washing to remove  unbound conjugates, 
chromogen solutions with tetramethylbenzidine  and urea peroxide 
were added to the wells. In the presence of the antigen-antibody-
antigen “sandwich” complex, the colourless  chromogens are 
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hydrolyzed by  bound HRP conjugate to  blue coloured  one. The 
blue colour turned into  yellow after stopping the reaction with 
sulfuric acid. The amount of colour can be measured and was 
proportional to the amount of antibody in the sample. Wells 
containing samples negative for anti-HBs remained  colourless. 
 
• Primary outcome measure,the sero conversion is defined as anti-HBs 
antibody titer greater than 10mIU/ml one month after completion of 
vaccine schedule. 
 
Statistical Analysis: 
 The data obtained were entered into SPSS 16 and 
analyzed.Categorical data were analyzed using chisquare test and continous 
variables with T test. P value less than 0.05 was taken as a significant one. 
 
Ethical Clearance 
 Obtained from Institutional  Ethics Committee, Madras Medical 
College Chennai. 
 
 Conflict of Interest  : Nil 
 Financial Support  : Nil 
 Limitation   : Small Sample Size 
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RESULTS 
 
 Our study  was a prospective comparative study comparing  the sero 
conversion rate following  4 doses of  40µg of recombinant Hepatitis B 
virus  vaccine (HBV  vaccine) administered to chronic kidney disease 
Stage-V patients undergoing haemodialysis (N=34)  to healthy adult 
volunteers with 3 doses of 20µg  recombinant HBV vaccine (N=30). This 
study was conducted in the Department of Nephrology ,Madras Medical 
College between  Feb.2012 to January 2014. Anti HBs titre was estimated 4 
weeks after the last dose of vaccination.Patients with antiHBs titre ≥ 
10mIU/ml were considered as immune responders and those with ≤ 
10mIU/ml were considered as non responders. 
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DEMOGRAPHY 
                             
SEX DISTRIBUTION 
Gender 
AntiHBS 
Total Non 
immune Immune 
Gender 
Female Count 1 6 7 Percentage 14.3% 85.7% 100.0% 
Male Count 5 22 27 Percentage 18.5% 81.5% 100.0% 
Total Count 6 28 34 Percentage 17.6% 82.4% 100.0% 
P =0.793  
 
 Among 34 patients in the study group, 7 were females(20.6%) and 27 
were males (79.4%).Thus men were the predominant group in this 
study.86% of females and 82% of males were found to be immune 
responders and there was  no statistically significant difference between 
them. 
 
SEX DISTRIBUTION 
 
 
  
79%
21%
MALES
FEMALES
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AGE DISTRIBUTION 
 
AGE 
 
AntiHBS 
Total Non 
immune Immune 
Age 
< 20 Count 1 2 3 Percentage 33.3% 66.7% 100.0% 
20 -30 Count 1 10 11 Percentage 9.1% 90.9% 100.0% 
30- 40 Count 1 5 6 Percentage 16.7% 83.3% 100.0% 
> 40 Count 3 11 14 Percentage 21.4% 78.6% 100.0% 
Total Count 6 28 34 Percentage 17.6% 82.4% 100.0% 
P=0.752 
 Age varied from 18 to 64 years with age of 35.88±12.13.Majority of 
them were more than 40 years old (41.2%) followed by 20-30 years age 
group(32.4%).There was no significant difference regarding immune 
response between different age groups. 
  
AGE DISTRIBUTION 
 
1 1 1
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< 20 yrs 20 -30 yrs 30 -40 yrs >40 yrs
NON IMMUNE
IMMUNE
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NATIVE KIDNEY DISEASE: 
          
      P=0.247  
  
 Chronic glomerulonephritis was the most common cause for chronic 
kidney disease in this study group(26.5%) followed by diabetic nephropathy 
(14.7%).Etiology was not known in 26.5% of patients. None of the disease 
was found to be significantly associated with immune response following 
HBV vaccine.p=0.247. 
 
NATIVE KIDNEY DISEASE 
 
0
1
2
3
4
5
6
7
8
9
10
ALPORT SYN CGN DM NOT KNOWN IGA OTHERS
NON IMMUNE
IMMUNE
Native kidney disease AntiHBS Total Non immune Immune 
NKD 
ALPORT Count 1 1 2 Percentage 50.0% 50.0% 100.0% 
CGN Count 0 9 9 Percentage 0.0% 100.0% 100.0% 
DM Count 2 3 5 Percentage 40.0% 60.0% 100.0% 
NOT KNOWN Count 2 7 9 Percentage   100% 
IGA Count 1 2 3 Percentage 33.3% 66.7% 100.0% 
OTHERS Count 0 6 6 Percentage 0.0% 100.0% 100.0% 
Total Count 6 28 34 Percentage 17.6% 82.4% 100.0% 
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DURATION OF DIALYSIS: 
 
 Duration of dialysis varied from 5 months to 23 months with mean of 
11.8±7.07 and most of them had undergone 6- 8 months (70.5%) of dialysis. 
This study did not show significant association between duration of dialysis 
and immune response.(p=0.714). 
Duration of Dialysis 
 
DURATION OF HD IN 
MONTHS 
Anti HBS Total 
Non 
immune Immune  
≤ 6 Count 2 5 7 Percentage 28.6% 71.4% 100.0% 
6 -12 Count 2 12 14 Percentage 14.3% 85.7% 100.0% 
12 - 18 Count 2 8 10 Percentage 20.0% 80.0% 100.0% 
18 - 24 Count 0 3 3 Percentage 0.0% 100.0% 100.0% 
Total Count 6 28 34 Percentage 17.6% 82.4% 100.0% 
P=0.714               
Duration of Dialysis 
 
 
 P=0.714 
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< 6 MON 6-12 MON 12-18 MON 18-24 MON
NON IMMUNE
IMMUNE
  
33 
 
COMORBID CONDITIONS: 
 
DIABETES MELLITUS 
 
P=0.267 
 
 
 Most of the patients in this study group  were non-diabetic (82.4%)) 
and only 17.6% were diabetic. Among 6 diabetic patients diabetic 
nephropathy was the underlying cause for chronic kidney disease in 5 of 
them. 85.7% of patients among non diabetics were immune responders 
compared to 66.7% among diabetics. 
 
 
                                                                                               
 
Diabetic status 
AntiHBS 
Total Non 
immune Immune 
NON DM Count 4 24 28 Percentage 14.3% 85.7% 100.0% 
DM Count 2 4 6 Percentage 33.3% 66.7% 100.0% 
Total Count 6 28 34 Percentage 17.6% 82.4% 100.0% 
18.%
82%
DIABETES MELLITUS
DIABETES
NON DIABETES
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HYPERTENSION: 
 
 
P=0.638 
 
 Almost all the patients in the study group had hypertension (97%) 
requiring 1 to 4 antihypertensives except one (3%). 
 
  
97%
3%
HYPERTENSION
YES
NO
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SMOKING: 
SMOKING 
AntiHBS 
Total Non 
immune Immune 
Non 
smokers 
Count 5 24 29 
Percentage 17.2% 82.8% 100.0% 
Smokers Count 1 4 5 
Percentage 20.0% 80.0% 100.0% 
Total Count 6 28 34 
Percentage 17.6% 82.4% 100.0% 
P=0.881 
 History of smoking was present in 5 patients (15%) and the remaining 
had denied the history of smoking (85%).Immune response rate was 83% 
and 82% between smokers and non smokers and it was statistically not 
significant. 
 
 
 
  
15%
85%
SMOKING
SMOKERS
NON SMOKERS
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BODY MASS INDEX: 
BMI 
AntiHBS 
Total Non 
immune Immune 
< 16 Count 1 2 3 
Percentage 33.3% 66.7% 100.0% 
16 -16.9 Count 0 3 3 Percentage 0.0% 100.0% 100.0% 
17 - 18.5 Count 0 2 2 Percentage 0.0% 100.0% 100.0% 
> 18.5 Count 5 21 26 Percentage 19.2% 80.8% 100.0% 
Total Count 6 28 34 Percentage 17.6% 82.4% 100.0% 
P = 0.654 
 
 Body mass index varied from 12.4 to 28.1 with mean of 20.1 ± 3.24. 
8 patients were malnourished with three of them had severe malnutrition 
(BMI < 16). Immune response was only 66.7% in severely malnourished 
patients compared to 80.8% in patients with BMI more than18.5 
                                       BODY MASS INDEX 
       
1
0 0
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3
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21
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<16 16 -16.9 17 -18.5 > 18.5
NON IMMUNE
IMMUNE
  
 
                                     
 Most of the patients (94%) were anemic with hemoglobin ranged 
from 4.7 to 11.6 gm/dl with mean of 7.28± 1.66. Only two patients (6%) had 
hemoglobin more than 11.gm/dl. Immune response was 100% in patients 
with hemoglobin more than 11.gm/dl 
   HB LEVEL
< 6.9 Count
Percentage
7 - 8.9 CountPercentage
9 -10.9 CountPercentage
> 11 CountPercentage
Total CountPercentage
P=0.423   
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BLOOD HAEMOGLOBIN: 
 
 
AntiHBs 
Non 
immune Immune 
 4 9 
 30.8% 69.2% 
 2 15 
 11.8% 88.2% 
 0 2 
 0.0% 100.0% 
 0 2 
 0.0% 100.0% 
 6 28 
 17.6% 82.4% 
HAEMOGLOBIN LEVELS 
 
7-8.9 9-10.9 > 11
2
0 0
15
2 2
Total 
13 
100.0% 
17 
100.0% 
2 
100.0% 
2 
100.0% 
34 
100.0% 
 
NON IMMUNE
IMMUNE
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BLOOD UREA: 
 
  Blood Urea level varied  from 58 mg/dl to 272 mg/dl with mean of 
134.08± 55.80. 21patients had blood urea of more than 100mg/dl.  
 
 
SERUM CREATININE 
             
CREATININE LEVEL 
AntiHBS 
Total Non 
immune Immune 
CREATINI
NE 
< 5 Count 1 4 5 
Percentage 20.0% 80.0% 100.0% 
> 5 Count 5 24 29 Percentage 17.2% 82.8% 100.0% 
Total Count 6 28 34 
Percentage 17.6% 82.4% 100.0% 
P = 0.88 
 
 
 Serum creatinine varied from 2.6 to 13.9 mg/dl with the mean of 7.45 
± 2.66. 29 Patients (85.3%) had Serum creatinine of  more 5 mg/dl. There 
was no significant difference regarding immune response between 
creatinine less than 5 or more than5 mg/dl. 
 
 
  
  
 
  
       
  P  = 0.13 
 
    
 Most of the  patients (76.5%) were inadequately dialyzed with Urea 
reduction ratio (URR) of  less than 65%. Immune response was 100% when 
URR was more than 65%.  
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20
ADEQUACY
URR 
< 65 
> 65 
Total 
39 
ADEQUACY OF DIALYSIS: 
 
ADEQUACY OF DIALYSIS 
 
> 65% URR
6
0
8
 
AntiHBS 
Non immune Immune
Count 6 20
Percentage 23.1% 76.9%
Count 0 8
Percentage 0.0% 100.0%
Count 6 28
Percentage 17.6% 82.4%
 
IMMUNE
NON IMMUNE
Total 
 
 26 
 100.0% 
 8 
 100.0% 
 34 
 100.0% 
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SERUM ALBUMIN: 
 
 
 
                  
ALBUMIN 
AntiHBS 
Total Non 
immune Immune 
ALBUM
IN 
< 4 Count 5 24 29 
Percentage 17.2% 82.8% 100.0% 
> 4 Count 1 4 5 Percentage 20.0% 80.0% 100.0% 
Total Count 6 28 34 
Percentage 17.6% 82.4% 100.0% 
 
 
P = 0.88 
 
 
 85% of patients undergoing dialysis had hypoalbuminaemia  
(< 4gm/dl) with only 15% had albumin level > 4gm/Dl. However the 
immune response rate was almost similar between the groups.  
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HCV  SEROLOGY: 
                          
HCV STATUS AntiHBS Total Non immune Immune 
HCV 
Negative Count 4 24 28 Percentage 14.3% 85.7% 100.0% 
Positive Count 2 4 6 Percentage 33.3% 66.7% 100.0% 
Total Count 6 28 34 Percentage 17.6% 82.4% 100.0% 
P=0.881 
 
 Among the study group patients 6 were (17.6%) HCV positive. 
Majority of HCV negative Serology patients (87.5%) have developed 
protective HBV immunity (>10mIU/ml) compared to 66.7% in HCV  
positive patients. 
 
HCV STATUS 
 
 
2 44
24
0
5
10
15
20
25
30
HCV POSITIVE HCV NEGATIVE
NON IMMUNE
IMMUNE
  
42 
 
 
 
 
ACCESS INFECTION 
 
                         
 
P = 0.324 
 
 
 Access Infection was present in 4 patients (11.8%). But all of them 
had antiHBs titers more than 10mIU/ml.  
 
  
ACCESS INFECTION 
AntiHBS 
Total Non 
immune Immune 
ACC 
INFECTION 
Absent 
Count 6 24 30 
Percentage 20.0% 80.0% 100.0% 
Present 
Count 0 4 4 
Percentage 0.0% 100.0% 100.0% 
Total 
Count 6 28 34 
Percentage 17.6% 82.4% 100.0% 
  
 
 
       
 
 
 AntiHBs titer varied from 5.7 to 79.4 mIU/ml with mean of 
24.71±16.09 in dialysis patients. Six of them (17.6%) had antiHbs 
10mIU/ml and 28 (82.4%) of patients had 
 
 
IMMUNE STATUS
Valid 
Non immune
Immune
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ANTIHBs TITER: 
titer > 10 mIU/ml.   
 
82%
18%
SEROCONVERSION
 Frequency 
 6 
 28 
Total 34 
titer < 
 
 
RESPONDER
NON RESPONDER
Percent 
17.6 
82.4 
100.0 
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CONTROL GROUP 
 
 
  30 healthy adult volunteers were included in this group . None of the 
persons in the control group had diabetes mellitus, hypertension or history 
of smoking. Blood sugar , blood urea and Serum Creatinine were with 
normal limits. Hepatitis-C and HIV Serology were negative for all of them.  
 
 
SEX DISTRIBUTION: 
 
Gender Frequency Percent 
Gender 
Female 20 66.7 
Male 10 33.3 
Total 30 100.0 
 
 
20 of them were females (67%) and 10 were males (33%) 
 
 
 
33%
67%
Sex distribution
MALE
FEMALE
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AGE DISTRIBUTION: 
    
Age Frequency Percent 
Age 
< 20 20 66.7 
20-30 4 13.3% 
30-40 6 20% 
Total 30 100.0 
 
 
 Age varied from 18 to 40 years with mean of 23.33±6.9 and most of 
them were less than 20 years (67%)  
                        
AGE DISTRIBUTION 
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BODY MASS INDEX : 
 
 
BMI Frequency Percent 
Valid 
16 - 16.9 1 3.3 
17 - 18.5 2 6.7 
> 18.5 27 90.0 
Total 30 100.0 
 
 BMI varied from 16.9 to 30.4 with mean of 22.74 ± 3.48. Most of 
them (90%) had BMI of more than 18.5 and only 10% had mild 
malnutrition.   
 
BODY MASS INDEX 
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SERUM  ALBUMIN  : 
       
  
Serum albumin level 
(gm/dl) Frequency Percent 
Valid 
< 4 22 73.3 
> 4 8 26.7 
Total 30 100.0 
 
 
 Serum Albumin level ranged from 3.1 to 4.3 wih mean of 3.63 ± 0.42.  
Most of them (73%) were hypoalbuminaemic.   
 
     
 
 
 
  
73%
27%
Serum albumin
< 4 gm/dl
> 4 gm/dl
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BLOOD  HAEMOGLOBIN 
 
 
Blood Haemoglobin level 
 
 
Frequency 
 
percentage 
 
 
Valid 
 
< 11gm/dl 
 
10 
 
33 
 
>11gm/dl 
 
20 
 
67 
 
 
 Blood Haemoglobin level varied between 9 and 14.4 gm/dl with 
mean of 11.85 ± 1.7. 20 (67%) had haemoglobin level more than 11 gm/dl 
and 10 (33%) of them had less than 11 gm /dl.But all of them were immune 
responders. 
 
 
 
 
 
 
33%
67%
HAEMOGLOBIN LEVEL
< 11 gm/dl
> 11 gm/dl
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                              SEROCONVERSION RATE  
 
AntiHBs titer: 
 
 
 
Group N Mean Std. Deviation 
Std. Error 
Mean 
ANTI 
HBS 
Patients 34 24.712 16.0995 2.7610 
Controls 30 31.870 20.4259 3.7292 
 
        P=0.123 
 
 
 
 AntiHBs titre varied from 10.1 to 76.4 mIU /ml with  mean of 
31.9±20.4. All of them had antiHbs titre more than 10mIU/ml(100%). 
Comparing the immune response in the study group and control group, in 
the control group the immune response was 100% and in the study group it 
was 82.4%. 
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PATIENTS AND CONTROLS 
IMMUNE RESPONSE 
 
      
 
 Immune response was 100% in healthy adult control group and it was 
82% in chronic kidney disease patients undergoing dialysis. 
 
 The mean  antiHBs titer level of patients was 24.7 and in healthy 
adult control group it was 31.8. 
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DISCUSSION 
  Hepatitis B virus infection is an important   health problem 
worldwide with nearly 2 billion people infected and about  350 million 
chronic carriers(1,2). Though there has been a marked  reduction  in the 
incidence of hepatitis B virus  infection in hemodialysis units compared to 
earlier data , probably due to screening of blood donors, decrease in blood 
transfusion requirements with more use  of  erythropoietin  and the 
development of guidelines for  infection control and vaccination, still there 
is  a higher prevalence  of HBV infection among hemodialysis patients  than 
in the general population .It is because of increased exposure to blood 
products and  shared hemodialysis equipment with impaired immune 
response in chronic kidney disease patients (3).  The prevalence of hepatitis 
B virus among Indian  dialysis population  varies from 20 to 45% but in 
Western countries it is < 1 %.(4,11)  
 
 The Centers for Disease Control and Prevention recommends that all 
dialysis patients should be vaccinated against HBV with double the standard 
dose (40µg) and intensified schedule (0, 1, 2, 6).  But the response in CKD 
patients on haemodialysis  even with intensified schedule  as recommended 
by CDC guideline  is low (50%-60%).(5,19) There are only very few  Indian 
studies available regarding immune response following  HBV vaccination 
and various factors   determining it in dialysis patients.We studied the 
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immune response in healthy individuals, in dialysis patients and   analyzed 
various factors that had an influence on immune response such as 
sex,age,duration of dialysis, diabetes, smoking, anaemia,  body mass index, 
albumin level and adequacy of dialysis. 
 
 In this study  we compared   the sero conversion rate following  4 
doses of  40µg of recombinant Hepatitis B virus  vaccine (HBV  vaccine) 
administered to chronic kidney disease Stage-V patients undergoing 
haemodialysis (N=34)  to healthy adult volunteers with 3 doses of 20µg  
recombinant HBV vaccine (N=30).AntiHBs titer ≥ 10mIU/ml (immne 
responder) was present in 82% of patients undergoing haemodialysis and 
the titre of >10Miu/ml was present in all the healthy control volunteers 
(100%). 
 
 Shepard  CW et al and Lai LL et al  in their studies showed that 
seroprotection rate in normal healthy individuals following standard-dose 
vaccination strategy of 3 doses of 0, 1, 2 months  with 20µg HBsAg with 
0.5mg aluminium salt as adjuvant was around 95% (12,58).Almost similar to 
this one, the seroprotection rate following 3 doses of 20 µg of HBV vaccine 
to healthy adults in our study was 100%. 
 
 But the seroprotection rate following 4 doses of 40 µg of HBV 
vaccine was reported to be 60% by  Tokar J I et al and Prabhat Singh et al 
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(12,15) in their studies. In our study the seroprotection rate was 82%.Some 
studies also observed the response rate of 80% in dialysis patients.(28). Also 
dialysis patients  develop lower peak antibody titer which persists for 
shorter duration than normal healthy population (17,18). In our study the mean 
antiHBs titer in dialysis patients was 24.7mIU/ml compared to 31.8mIU/ml 
in healthy individuals. 
 
 Among 34 patients in this  study group, 7 were females(20.6%) and 
27 were males (79.4%).Thus men were the predominant group.86% of 
females and 82% of males were found to be immune responders and there 
was  no statistically significant difference between them regarding immune 
response. In a study by Hans Kohler et al  , 66% of female patients and 50% 
of male dialysis patients developed seroconversion following HBV  
vaccine.However he had found that the sex difference for seroconversion 
rate was not   statistically significant.(40) 
 
 In our study age varied from 18 to 64 years with mean age of 
35.88±12.13.Majority of them were more than 40 years old (41.2%) 
followed by 20-30 years age group(32.4%).There was no significant 
difference regarding immune response between different age groups.But  
Fabrizi et al and Fisman DN et al  (41,38) in their  meta-analysis of the effect 
of age on immune response to HBV vaccination in chronic kidney disease 
patients on haemodialysis  found a decrease in serological response with 
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older age.   Also Hans Kohler in his study shown that the mean age of 
patients who develop immune response was 39.8 years compared to patients 
with  52.8 years who did not develop immune response. 
 
 None of the native kidney disease was found to be significantly 
associated with immune response following HBV vaccine in this study 
group as in other studies (42 -44). Duration of dialysis in our study population  
varied from 5 months to 23 months with mean duration  of 11.8±7.07 and 
most of them had undergone 6- 8 months (70.5%) of dialysis.There was no  
significant association seen between duration of dialysis and immune 
response in our study population. According to Hans Kohler et al the mean 
length of the time on dialysis had no impact on immune response.(40)  
 
 Most of the patients in this study group  were non-diabetic (82.4%) 
and only 17.6% were diabetic. Among 6 diabetic patients, diabetic 
nephropathy was the underlying cause for chronic kidney disease in 5 of 
them.85.7% of patients among non diabetics were immune responders 
compared to 66.7% among diabetics.Thus the immune response rate was 
better in non diabetics (85.7%) compared to the diabetics (66.7%). Sarah F. 
Schillie et al and Alavian et al (32,33) in their  systematic reviews  reported the  
sero protection rate after HBV vaccination in patients  with diabetes varied 
from 34% to 80%. Most of the studies also confirmed this.But Lacson et al 
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(62)
 reported null association between diabetes and immune response in 
dialysis patients. 
 
 History of smoking was present in 5 patients (15%) and the remaining  
were non smokers (85%).Immune response rate was 83% and 82% between 
smokers and non smokers respectively and it was statistically not 
significant.Thus in our study smoking had no effect on vaccine response but 
other studies by Kara IH et al (17) also have shown the negative impact of 
smoking on immune response following vaccination. 
 
 Our study population’s body mass index varied from 12.4 to 28.1 
with mean of 20.1 ± 3.24. 8 patients(23.5%) were malnourished with 3 
(8.8%) of them having severe malnutrition(BMI<16). Immune response was 
only 66.7% in severely malnourished patients compared to 80.8% in 
patients with BMI more than 18.5. Fernandez et al (36) in their study on 
effect of malnutrition on HBV vaccination response, morbidity and 
mortality in haemodialysis patients showed the negative influence of 
malnutrition on vaccine response.Nutritional status  was assessed by  serum 
albumin, prealbumin, anthropometric measurements,mid arm  
circumference  and triceps skinfold thickness . Responders had significantly 
high levels of serum albumin, prealbumin and predialysis blood urea 
concentration compared to non-responders. Malnutrition reduces  the ability 
to form antibodies and hence impaired response to HBV vaccination. 
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Malnutrition also increases the risk of morbidity and mortality in dialysis 
patients.Thus it is  well clear that malnutrition and poor immune response 
are interconnected, but other factors also influence immune 
responsiveness.In this study it was shown that  Serum albumin and 
predialysis serum urea levels were the strongest predictors of response to the 
HBV vaccination. Also Fabrizi F et al (37) in his  meta analysis of seven 
studies on  the impact of nutritional status on HBV  vaccination response  in 
CKD patients  showed that the poor nutritional status as  estimated by serum 
albumin levels was  an independent and adverse factor on immune response  
after HBV vaccination in chronic kidney disease patients. In our study also 
the immune response was less compared to patients with good nutritional 
status. 
                 In our study most of the patients (94%) were anemic with 
hemoglobin ranged from 4.7 to 11.6 gm/dl with mean of 7.28± 1.66. Only 
two patients (6%) had hemoglobin more than 11.gm/dl. Immune response 
was 100% in patients with hemoglobin more than 11.gm/dl.Anaemia has a 
negative impact on immune response (57,58). Most of the  patients (76.5%) in 
our study population  were inadequately dialyzed with Urea reduction ratio 
(URR) of  less than 65%. Immune response was 100% when URR was more 
than 65%. Khalid Al Saran et al  showed that there no statistically 
significant association between adequacy of dialysis and immune 
response.But in our study the response rate was very good with adequate 
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dialysis but  statistical significance was not present in view small sample 
size as by Fraser GM(39).85% of patients undergoing dialysis had 
hypoalbuminaemia(< 4gm/dl) and  only 15% of patients  had albumin level 
> 4gm/dl.However the immune response rate was almost similar between 
the groups.Fernandez et al (36) in their study reported the negative influence 
of nutritional status as assessed by serum albumin on immune response.But 
few studies also had shown that nutritional state had no effect on 
vaccination responsiveness. 
 
 Among  our study group patients 6 were (17.6%) HCV positive. 
Majority of HCV negative Serology patients (87.5%) have developed 
protective HBV immunity (> 10mIU/ml) compared to 66.7% in HCV  
positive patients. Some studies reported the negative impact of coexisting 
HCV  infection on immune response (28,63). Our study also had shown poor 
response in HCV positive  patients. Access Infection was present in 4 
patients (11.8%). But all of them had antiHBs titre more than 10mIU/ml. 
This showed the negative correlation of the presence of infection and the 
response following vaccination. 
 
 In our study   30 healthy adult volunteers were included. None of 
them  in the control group had diabetes mellitus, hypertension or history of 
smoking. Blood sugar , blood urea and Serum creatinine were within normal 
limits. Hepatitis-C and HIV Serology were negative for all of them. Hence 
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we did not compare both the groups regarding all these parameters.Most of 
them in control group were females and less than 20 years.Body mass index 
was normal in almost in all of them but serum albumin level was less than 4 
gms/dl in many of them.None of the factors had an influence on immune 
response. 
 
 To summarize,  our study had  shown  good immune response  in 
healthy adult population (100%) than chronic kidney disease  stage v 
patients undergoing dialysis (82%). 
 
Limitation of the study: 
 Small sample size (N =34) of patients undergoing dialysis and healthy 
adult  volunteers (N=30) is an important limitation of the study. 
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CONCLUSION 
 
1. The seroconversion rate in chronic kidney disease Stage-V patients 
undergoing haemodialysis  following  4 doses of  40µg of 
recombinant hepatitis B virus  vaccine  in our study was 82%. 
2. The seroconversion rate in  healthy adult volunteers with 3 doses of 
20µg  recombinant HBV vaccine in our study was 100%. 
3. Female patients undergoing dialysis  showed  better immune response 
than males. 
4. Non diabetic patients showed better immune response than diabetic 
patients. 
5. Patients with higher body mass index had higher seroconversion rate 
than patients with malnutrition. 
6. Patients with higher haemoglobin level had better response. 
7. Adequately dialyzed patients were found to have  better immune 
response. 
8. Age,duration of dialysis and serum albumin had no impact on 
immune response following HBV vaccination.  
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